Investor Presentaiton

Delivered on our key strategic priorities in Q3 2023 < < > Advanced the pipeline to meet patient unmet need Executed on strategic business development to augment pipeline Achieved strong commercial and financial performance Created long-term value for patients and shareholders Daiichi-Sankyo & MERCK MERCK 5

View entire presentation